(Last updated : 2024-08-28 14:50:35)
  Seiko Sugiyama
   Department   Kawasaki Medical School  Kawasaki Medical School, Department of Dermatology,
   Position   Assistant Professor
■ Present specialized field
Dermatology 
■ Journal
1. 2023/09/11 Biomarkers for predicting immune reconstitution inflammatory syndrome in dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid: A retrospective observational study with a case series 
2. 2023/05/14 Positron emission tomography and computed tomography imaging in primary cutaneous nocardiosis with osteomyelitis clinically mimicking soft tissue sarcoma 
3. 2023/04/17 Dramatic deterioration or new-onset dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid after COVID-19 vaccination: A possible manifestation of immune reconstitution inflammatory syndrome 
4. 2022/07 Clinical features of dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid in Japan: A nationwide retrospective observational study. 
5. 2022/06 Anti-Cytomegalovirus Therapy: Whether and When to Initiate, Those Are the Questions 
Display all(20)
■ Presentation
1. 2023/05/11 The predictive and diagnostic biomarkers of immune-related adverse events vary by the affected organ (Poster notice,General) 
2. 2022/12/02 Cytokine profiles for predicting the development of COVID-19 vaccine-associated bullous pemphigoid (Speech,General) 
3. 2021/12/03 Occurrence of immune reconstitution inflammatory syndrome can be predicted by cytokine profiles in dipeptidyl peptidase-4 inhibitors-associated bullous pemphigoid (Speech,General) 
4. 2020/12/11 Neutrophil-to-lymphocyte ratio as a useful biomarker can predict outcomes in dipeptidyl peptidase-4 inhibitor associated bullous pemphigoid (Poster notice,General)